30 results about "Genus Streptococcus" patented technology

The present invention provides methods for tagging and/or identifying microorganisms. In some preferred embodiments, the microorganisms are bacteria. In some particularly preferred embodiments, the bacteria are members of the genus Streptococcus, while in other embodiments, the bacteria are members of other genera. The present invention also provides microorganisms tagged using the methods set forth herein. In some preferred embodiments, the tagged microorganisms are bacteria. In some particularly preferred embodiments, the tagged bacteria are members of the genus Streptococcus, while in other embodiments, the tagged bacteria are members of other genera.

The invention discloses a gene chip of aquatic product cultivation pathogenic bacterium, comprising a solid phase carrier which is modified chemically, a detection probe and a quality control probe are distributed on the solid phase carrier in a dot matrix way; the detection probe comprises specificity 16S rDNA sequences and/or gyrB gene sequences of vibrio, comma bacillus, vibrio harveyi, vibrio alginolyicus, vibrio anguillarum, vibrio parahemolyticus, nocardia, nacardia seriolea, aeromonas, hydrophilic aeromonas, streptococcus and dolphin streptococcus, which are to be detected, the quality control probe includes PCR positive, chip fixed positive control, chip hybridizing negative control, chip hybridizing positive control and chip hybridizing blank control; the gene chip has the advantages of small volume and high flux, can detect known and unknown germs of the vibrio, the nocardia, the aeromonas and the streptococcus, and can detect specific germs with multiple kinds, and the simpleness and rapidness and specificity of the germs can be detected, and automatic detection can be carried out after detection software is additionally arranged.

The invention discloses application of elsholtzia volatile oil in anti-bacteria and antibiotic resistant bacteria. The elsholtzia volatile oil is extracted by steam distillation. The elsholtzia volatile oil has certain functions of killing and/or inhibiting growth on bacteria of staphylococcus, escherichia coli, candida, pseudomonas, enterobacter, streptococcus and the like and fungi. The elsholtzia volatile oil has certain functions of killing and/or inhibiting growth on bacteria of drug-resistant staphylococcus, drug-resistant escherichia coli, drug-resistant enterobacter, drug-resistant klebsiella, drug-resistant pseudomonas, drug-resistant acinetobacter, drug-resistant streptococcus, and drug-resistant enterococcus and the like. The elsholtzia volatile oil can be used in industries offood, medicine, health care products, cosmetics and the like and can be used for preparing various forms of products with antibacterial and antibiotic resistant bacteria functions, and belongs to thenew application field of the elsholtzia volatile oil.

PCT No. PCT/EP96/00309 Sec. 371 Date Oct. 28, 1997 Sec. 102(e) Date Oct. 28, 1997 PCT Filed Jan. 24, 1996 PCT Pub. No. WO96/23896 PCT Pub. Date Aug. 8, 1996A new bacteria species within the genus Streptococcus is disclosed, designated as Streptococcus sp PT DSM 8747. From this bacteria species a lipoteichoic acid LTA can be isolated which has a lipid anchor, galacto-furanosyl-beta-1-3-glycerol with different rests of fatty acids esterified to the two adjacent hydroxy groups in the glycerol moiety and a non-glycosylated, linear, unbranched GroP chain. The hydrophilic backbone may comprise 10 glycerophosphate units esterified with D-alanine in an extent of about 30%. The invention further concerns a pharmaceutical composition with the LTA, optionally together with a monokine and/or hyaluronidase, a method of treating cancer comprising administrating an antitumor effective amount thereof, a method of producing the LTA, and degradation products of the LTA and their use.

The invention discloses escherichia coli recombinant bacteria capable of high-producing 2, 5-dimethylpyrazine and a construction method of the escherichia coli recombinant bacteria, and belongs to thetechnical field of gene engineering. According to the escherichia coli recombinant bacteria and the construction method thereof, a genetic engineering method is applied, L-threonine dehydrogenase TDHis overexpressed in escherichia coli K-12 capable of high-producing L-threonine, and NADH oxidase NoxE derived from lactococcus microorganisms and aminoacetone oxidase AAOSO derived from streptococcus microorganisms are expressed in a heterologous manner, and meanwhile 2-amino-3-ketobutyric acid CoA ligase KBL and primary amine oxidase TynA are knocked out, so that a novel and efficient 2, 5-dimethylpyrazine synthetic route is constructed, and the problem of unbalance of cofactors in the recombinant bacteria is solved. By taking escherichia coli E. coli THR as an example, the accumulation amount of 2, 5-dimethylpyrazine reaches 1.2 +/-0.2 g/L through a 36h shaking flask fermentation experiment of the recombinant bacteria. According to the method, L-threonine high-producing strains are used as starting strains, the synthetic route of 2, 5-dimethylpyrazine in escherichia coli is successfully reconstructed, the defect of unbalanced intracellular cofactors is improved, and a new idea is provided for breeding 2, 5-dimethylpyrazine.

The invention relates to a slow-releasing agent or rslow-releasing implanting agent containing antibiotics. The injection comprises slow-releasing micro-sphere and dissolvent. The slow-releasing micro-sphere contains slow-releasing findings and antibiotics, and dissolvent contains suspending adjuvant agent such as sodium carboxymethyl cellulose with the adhesive degree being 100cp-3000cp (at 20-30 Deg. C). The slow-releasing findings comprises EVAc, polyphenyl, PLA, PLGA, decanedioic acid copolymer, albumen glue and gelatin; the slow-releasing implanting agent is prepared with slow-releasing micro-sphere or through other methods. When said antibiotics is placed or injected into bacteria, the medicine can be released slowly for more than 10 days, and toxicity is dramatically reduced at the same time when effective medicine concentration is got and maintained. The said slow-releasing agent is specially effective for chronic medullitis, bedsore, intractable ulcer on skin, diabetes femoral head necrosis and other abscessus, which are caused by Staphylococcus, Streptococcus, Streptococcus, acne Propionibacteriaceae, Enterobacter, Enterobacter, gonotoxin or parameningococcus.

The invention discloses application of bacteriostatic and drug-resistance bacteria prevention functions of clove essential oil. The clove volatile oil is extracted through a water vapor distillation method, and the clove volatile oil has certain killing and/or growth inhibition functions on bacterial and fungi such as staphylococcocci, escherichia coli, candida, pseudomonades, enterobacter and streptococcocci. The clove volatile oil has certain killing and/or growth inhibition functions on viruses such as drug-resistance staphylococcocci, drug-resistance escherichia coli, drug-resistance enterobacter coli, drug-resistance klebsiella, drug-resistance pseudomonades, drug-resistance acinetobacter, drug-resistant streptococcocci and drug-resistant enterococcocci. The clove volatile oil can beapplied to industries such as food, medicine, health-care products and cosmetics, and can be prepared into various products with the bacteriostatic and drug-resistance bacteria prevention functions. The invention belongs to the field of novel application of the clove volatile oil.

The invention relates to a loop-mediated isothermal amplification primer for detecting streptococcus agalactiae of tilapias. The primer is designed according to a conserved sequence of a surface immunogenic gene of the streptococcus agalactiae of the tilapias and comprises sip-F3, sip-B3, sip-FIP and sip-BIP respectively shown by SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4. A loop-mediated isothermal amplification method for detecting the streptococcus agalactiae of the tilapias can be established according to the designed primer. In the method, cross reactions with several common pathogenic bacteria of aquatic animals and several common pathogenic bacteria of streptococcus cannot happen. The detection method provided by the invention does not need expensive instruments, and is short in time, simple in operation and high in sensitivity.

The invention discloses a kefir fermented dairy product and a preparation method thereof. The kefir fermented dairy product comprises the following raw materials in percentage by weight: 0.001-0.2% ofa composite strain, 0-10% of sugar, 0-0.1% of acidic fruit juice and the balance of animal milk, wherein the composite strain is at least one selected from lactococcus, lactobacillus, bifidobacterium, streptococcus and leuconostoc. According to the invention, fermentation characteristics of different strains are utilized to optimize strain combination and process conditions, and a production process meeting requirements of national laws and regulations is obtained, so that flavor and quality of traditional kefir products can be kept, and industrial production of kefir products can be realized. Meanwhile, through a stirring fermentation process and addition of acidic fruit juice, citric acid metabolic pathway products of the strains can be improved, and Kafel flavor and bubble taste of theproduct can be enhanced.

The invention discloses a bifidobacterium bifidum probiotic solid beverage capable of resisting cell aging, and relates to the technical field of probiotic beverage production. A preparation method comprises the steps of S1, selecting various raw materials used for processing the probiotic solid beverage, wherein the raw materials comprise bifidobacterium bifidum, lactobacillus and streptococcus,a fruit juice mixture, skim milk, prebiotics, soybean protein powder, amino acids and water; and S2, mixing the fruit juice mixture with skim milk, adding soybean protein powder and a proper amount ofwater, performing stirring, and performing sterilizing at 121 DEG C for 15 minutes. According to the bifidobacterium bifidum probiotic solid beverage capable of resisting cell aging, through reasonable activation and fermentation treatment, bifidobacterium bifidum and lactobacillus generate a good synergistic promotion effect, so that the content of viable bacteria of bifidobacterium bifidum is increased, and the biological activity of bifidobacterium bifidum is improved, so that the effects of resisting cell aging, delaying body aging, enhancing immunity and the like of the bifidobacterium bifidum are ensured.

The invention provides a streptococcus, which is a new species in streptococcus, is named as Streptococcus sp.76, is registered and preserved in Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No: 60774. The streptococcus sp.76 disclosed by the invention can generate relatively strong bacteriostatic active substances after being subjected to fermentation culture, has a relatively obvious bacteriostatic effect on staphylococcus aureus, salmonella typhi and the like, and has a wide development space in prevention and treatment of diseases caused by the staphylococcus aureus, the salmonella typhi and the like; good development and application prospects are realized in the aspect of antibacterial drugs.

The present invention relates to a lactic acid bacterium, in particular a strain of the Streptococcus genus, with reduced sensitivity to cos-type bacteriophages. The invention also relates to methods to engineer these lactic acid bacteria as well as their use to ferment milk.

The invention provides a medical composition for skin wound healing. Specifically, the composition is a soybean fermentation composition which is soybean fermentation liquid prepared through co-culture of soybean liquid and one or more microbial probiotics flora, wherein a microbial probiotics flora formation is a group constituted by microorganisms of bifidobacterium, lactobacillus, bacillus, lactococcus and streptococcus. Healing of skin wounds can be effectively promoted, and the problems of chronic wound healing and difficult wound healing are solved.

The invention discloses a marker for predicting the curative effect of tumor chemotherapy combined with immunotherapy and application of the marker, and belongs to the technical field of biological medicine, the marker is at least one microorganism selected from streptococcus, fusobacterium, peptostreptococcus, micromonas and carbodiimide in tumor tissue; according to the present invention, the corresponding microorganism expression condition of the tumor tissue of the patient is detected by using the 16sRNA, and then the main coordinate analysis and the AUC prediction titer calculation are performed on the corresponding data to obtain the microorganism variety capable of predicting the chemotherapy-immunotherapy combined treatment effect of the esophageal cancer patient, such that compared with the currently reported tools for predicting the immunotherapy prognosis, such as PD1, PD-L1, and the like, the application has the advantages of higher accuracy, rapidness, convenience, lower price and the like.

Described herein are methods and compositions for treating immune checkpoint inhibitor (ICI)-associated colitis in a subject comprising administering fecal matter from a healthy donor to the subject. Further aspects of the disclosure relate to a method of treating immune checkpoint inhibitor (ICI)-associated colitis in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Escherichia, Akkermansia, Bacteroides, Lachnospiraceae, Blautia, Tyzzerella, Bifidobacterium, Streptococcus, Colinsella, and Fusicatenibacter.